Record ID: MS-N063 · Family: Acupuncture / symptom support · Clinical question: In breast cancer survivors with frequent bothersome hot flashes, does electroacupuncture reduce hot-flash burden?
Evidence label: Promising phase II evidence; interpretation is limited by small groups and an unusual four-arm comparison.
Evidence at a glance
- Benefit: Hot-flash scores improved in all four groups; electroacupuncture had the largest average reduction at weeks 8 and 24.
- Certainty: Low to moderate. The trial’s primary formal comparison was sham acupuncture versus placebo pill, not every pairwise contrast.
- Risk: Adverse effects were less frequent with electroacupuncture than gabapentin in this trial, but needling risks remain.
- Cancer control: Not studied.
What was studied
A phase II trial randomized 120 breast cancer survivors with at least two bothersome hot flashes per day to eight weeks of electroacupuncture, sham acupuncture, gabapentin or placebo pill. The primary endpoint was change in hot-flash composite score at week 8. The formal design focused on comparing the two placebo groups while estimating intervention effects.
Gabapentin was studied as a systemic comparator; the research regimen should not be treated as personal prescribing advice.
What the results show
At week 8, mean hot-flash composite-score reductions were −7.4 with electroacupuncture, −5.9 with sham acupuncture, −5.2 with gabapentin and −3.4 with placebo pill (overall P<.001). At week 24, reductions were −8.5, −6.1, −2.8 and −4.6, respectively (overall P=.002). Adverse effects were reported in 16.7% with electroacupuncture, 3.1% with sham, 39.3% with gabapentin and 20% with placebo pill.
The larger change with electroacupuncture is encouraging, but it should not be read as a definitive head-to-head superiority claim across all four arms.
Limits and uncertainty
Each arm was small, blinding differed between pill and procedure groups, and the trial was not powered for every possible pairwise comparison. Hot flashes fluctuate and are sensitive to expectation and attention. Results may differ by endocrine therapy, menopause status, acupuncture protocol and baseline severity. Longer-term comparative effectiveness and cost are uncertain.
Safety and practical context
Hot flashes can be worsened by medicines, thyroid disease, infection, anxiety, alcohol and other triggers. Medication choices must be coordinated with oncology, especially with endocrine therapy. For acupuncture, review platelet and neutrophil counts, anticoagulation, infection, implanted devices and skin integrity. Electroacupuncture may be unsuitable with some implanted electrical devices.
Questions for the care team
- Could a cancer treatment or another condition be driving the hot flashes?
- What nonhormonal medical and behavioral options fit the treatment plan?
- How will frequency and severity be tracked before and after a time-limited trial?
Sources checked
- Randomized phase II trial (PMID 26304905; PMCID PMC4622101)
- Trial registration NCT01005108
- Journal report and DOI
Last literature search: October 18, 2026 · Record appraisal: October 18, 2026
Educational evidence summary, not personal medical advice. This record concerns symptom or supportive care. It does not establish tumor shrinkage, recurrence prevention or longer survival, and it should not delay or replace oncology treatment.
